Online citations, reference lists, and bibliographies.
← Back to Search

Perisphincteric Injection Of Botulinum Toxin Type A

D. Zermann, M. Ishigooka, J. Schubert, R. Schmidt
Published 2000 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Background: Chronic prostatic pain is still a diagnostic and therapeutic problem. The clinical observation that prostatic and pelvic pain is accompanied by motoric and sensoric disorders of the pelvic floor muscles led to the hypothesis that prostatic pain roots in a changed processing of afferent and efferent information with the central nervous system (CNS).Methods: Neuro–urological work–up of 11 male patients with chronic prostatic pain was completed. This included a clinical evaluation of pelvic floor function, urodynamic investigation of bladder and urethra function and a cystoscopy to exclude morphological aberrations. A transurethral perisphincteric injection of 200 units botulinum toxin type A (BTX) was followed by a 2– to 4–week visit to evaluate their influence on the neuro–urological symptomatology.Results: All chronic prostatic pain patients suffered from a pathological pelvic floor tenderness, an inability of sufficient conscious pelvic floor control, a urethral hypersensitivity/hyperalgesia and a urethral muscle hyperactivity. Basic parameters of bladder function (capacity, sensitivity, compliance) were normal. The BTX injection was followed by a pelvic floor muscle weakening and a relief of prostatic pain and urethral hypersensitivity/hyperalgesia. A botulinum–related decrease of the functional urethral length, the urethral sphincter closure pressure, the postvoid residual volume and an increase of the peak and average uroflow were objectivated.Conclusion: A weakening of the urethral sphincter muscle via blocking acetylcholine release by BTX injection is followed by pain relief and symptom improvement. It can therefore be concluded that a barrage of nociceptive information from the dysfunctional pelvic floor overflood the CNS and induce a changed CNS processing. Interrupting the efferent branch of the disturbed central circle is one opportunity to treat chronic prostatic pain.
This paper references
10.1002/PROS.2990060413
Chronic prostatitis: Comments on infectious etiologies and antimicrobial treatment
R. Greenberg (1985)
10.1002/ANA.410410209
Botulinum toxin treatment of muscle cramps: A clinical and neurophysiological study
L. Bertolasi (1997)
10.1093/BRAIN/120.4.571
Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp. A PET study.
A. O. Ceballos-Baumann (1997)
10.1016/0090-4295(87)90193-2
Neuromuscular dysfunction in nonbacterial prostatitis.
W. Hellstrom (1987)
10.1038/264787A0
Effect of botulinum toxin on trophic regulation of acetycholine receptors
A. Pestronk (1976)
10.1113/jphysiol.1984.sp015475
Muscle but not cutaneous C‐afferent input produces prolonged increases in the excitability of the flexion reflex in the rat.
P. Wall (1984)
10.1016/0090-4295(90)80214-8
Prostatodynia o painful male urethral syndrome
George A. Rarbalias (1990)
10.1523/JNEUROSCI.06-05-01433.1986
Relative effectiveness of C primary afferent fibers of different origins in evoking a prolonged facilitation of the flexor reflex in the rat
C. Woolf (1986)
10.1126/SCIENCE.785600
Botulinum toxin: mechanism of presynaptic blockade.
I. Kao (1976)
10.1136/jnnp.55.9.844
Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system.
P. Girlanda (1992)
10.1016/0006-8993(75)90323-6
Muscle receptors with group IV afferent fibres responding to application of bradykinin
M. Franz (1975)
Urinary incontinence update: old traditions and new concepts.
R. Schmidt (1999)
10.1002/ANA.410290407
Change in pattern of muscle activity following botulinum toxin injections for torticollis
D. Gelb (1991)
10.1016/0304-3959(93)90161-H
Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence
T. J. Coderre (1993)
10.1016/0165-1838(81)90059-X
Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine.
W.C. de Groat (1981)
10.1016/S0090-4295(96)00421-9
Chronic pelvic pains represent the most prominent urogenital symptoms of "chronic prostatitis".
J. Krieger (1996)
10.1016/0028-3908(87)90075-X
Peptides as neuromodulators in primary sensory neurons
A. Cuello (1987)
10.1016/S0022-5347(01)66376-6
Botulinum-A Toxin as a Treatment of Detruosor-Sphincter Dyssynergia: A Prospective Study in 24 Spinal Cord Injury Patients
B. Schurch (1996)
10.1523/JNEUROSCI.09-08-02902.1989
Neurotransmission regulates stability of acetylcholine receptors at the neuromuscular junction
O. Avila (1989)
10.1212/WNL.46.4.1158
Botulinum toxin treatment in the facial muscles of humans
R. Eleopra (1996)
10.1016/S0022-5347(01)61802-0
Neurourological insights into the etiology of genitourinary pain in men.
D. Zermann (1999)
Free nerve endings in skeletal muscle of the cat.
Stacey Mj (1969)
10.1016/S0022-5347(17)56309-0
Prostatosis, prostatitis or pelvic floor tension myalgia?
J. Segura (1979)
10.1016/0165-0173(90)90002-6
Contributions of dendritic spines and perforated synapses to synaptic plasticity
R. Calverley (1990)
10.1038/313054A0
Calcitonin gene-related peptide is a potent vasodilator
S. Brain (1985)
10.1016/0306-4522(88)90064-4
Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides
P. Holzer (1988)
The origin, structure, and pharmacological activity of botulinum toxin.
L. Simpson (1981)
10.1097/00002341-199103000-00007
Innervation Zone of Orbicularis Oculi Muscle and Implications for Botulinum A Toxin Therapy
G. Borodic (1991)
10.1016/0304-3959(89)90135-8
Expansion of receptive fields of spinal lamina I projection neurons in rats with unilateral adjuvant-induced inflammation: the contribution of dorsal horn mechanisms
J. L. Hylden (1989)
10.1016/S0022-5347(01)66870-8
Bacterial infection in prostatodynia.
J. Lowentritt (1995)
10.1016/S0090-4295(99)80048-X
Prostatodynia and interstitial cystitis: one and the same?
J. Miller (1995)
10.1056/NEJM199104253241707
Therapeutic uses of botulinum toxin.
J. Jankovic (1991)
10.1113/jphysiol.1961.sp006689
Participation by pressure—pain receptors of mammalian muscles in the flexion reflex
A. Paintal (1961)
10.1016/0304-3959(93)90027-M
Nociception from skeletal muscle in relation to clinical muscle pain
S. Mense (1993)
10.1093/BRAIN/118.3.801
Physiological effects produced by botulinum toxin treatment of upper limb dystonia. Changes in reciprocal inhibition between forearm muscles.
A. Priori (1995)
10.1111/j.1476-5381.1987.tb10281.x
Plasma protein extravasation induced by mammalian tachykinins in rat skin: influence of anaesthetic agents and an acetylcholine antagonist
R. Couture (1987)
10.1113/jphysiol.1977.sp012088
Thin‐fibre receptors responding to mechanical, chemical, and thermal stimulation in the skeletal muscle of the dog
T. Kumazawa (1977)



This paper is referenced by
10.1007/S11916-007-0218-0
Myofascial dysfunction associated with chronic pelvic floor pain: Management strategies
A. Srinivasan (2007)
10.1007/S11884-011-0096-5
Neurotoxin Use for Voiding Dysfunction
H. Wang (2011)
10.1038/ncpuro0438
Traditional therapy for chronic pelvic pain does not work: what do we do now?
R. Anderson (2006)
10.1007/PL00007819
Botulinum toxin: evidence-based medicine criteria in rare indications
W. Jost (2001)
10.4111/KJU.2006.47.1.47
The Effect of Botulinum Toxin and Resiniferatoxin on the Detrusor Overactivity Induced by Cyclophosphamide in Rat Bladder
S. Kim (2006)
10.1016/j.eururo.2008.05.007
Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats.
Yao-Chi Chuang (2009)
10.1159/000079687
Pain and Its Treatment in Urology
Guido Tenti (2004)
10.1186/1471-2490-7-17
Pelvic tenderness is not limited to the prostate in chronic prostatitis/chronic pelvic pain syndrome (CPPS) type IIIA and IIIB: comparison of men with and without CP/CPPS
R. Berger (2007)
10.1159/000317517
The Unusual History and the Urological Applications of Botulinum Neurotoxin
V. Hanchanale (2010)
10.1016/S1879-5226(10)60036-X
Current Management of Male Chronic Pelvic Pain Syndromes
Y. Juan (2010)
10.1002/nau.20403
Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
I. Ghalayini (2007)
10.1016/j.eururo.2009.08.020
EAU guidelines on chronic pelvic pain.
M. Fall (2010)
10.3390/toxins12040214
A Proposal for Botulinum Toxin Type A Injection Into the Temporal Region in Chronic Migraine Headache
Young-Gun Kim (2020)
10.1016/S0302-2838(03)00250-1
Botulinum toxin as a new therapy option for voiding disorders: current state of the art.
T. Leippold (2003)
10.1007/S11934-004-0088-5
Urologic applications of botulinum toxin therapy for voiding dysfunction
R. Rackley (2004)
10.1038/nrurol.2015.193
Current and potential urological applications of botulinum toxin A
Y. Jiang (2015)
10.1016/j.ucl.2010.06.001
Botulinum toxin therapy for neurogenic detrusor overactivity.
M. Smaldone (2010)
10.1007/978-3-642-03580-7_7
Botulinum Toxin Injection for Prostate Disorders
M. Chancellor (2011)
10.1111/j.1464-410X.2003.04714.x
Botulinum toxin and its applications in the lower urinary tract
M. Harper (2004)
10.3109/9781420021196-37
Pelvic Floor Muscle Dysfunction and Pelvic Pain
B. Messelink (2007)
10.1007/978-3-642-03580-7_5
BoNT for Bladder and Pelvic Pain
M. Chancellor (2011)
10.1038/sj.bjp.0706637
Purinoceptors as therapeutic targets for lower urinary tract dysfunction
A. Ford (2006)
10.1089/089277904773582804
Chronic prostatitis/chronic pelvic pain syndrome: is there a role for local drug infiltration therapy?
A. El-Hakim (2004)
10.1002/NAU.20090
Botulinum toxin for the treatment of lower urinary tract symptoms: A review
A. Sahai (2005)
10.1016/J.UROLOGY.2004.09.001
Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.
A. Sahai (2005)
10.1007/S11934-005-0035-0
Urologic applications of botox
C. Moore (2005)
10.3390/toxins7062232
Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection
J. Jhang (2015)
10.1007/s00192-005-0028-z
Botox in urology
A. Thwaini (2005)
10.1016/J.JURO.2006.07.127
The application of botulinum toxin in the prostate.
Yao-Chi Chuang (2006)
10.6259/IPFD.2008.2.2.41
Technical Points of Botulinum Toxin a Injections in the Treatment of Lower Urinary Tract Dysfunction
Hann-chorng Kuo (2008)
10.1016/J.UROLOGY.2004.06.073
Botulinum toxin a has antinociceptive effects in treating interstitial cystitis.
C. Smith (2004)
10.1007/978-3-319-56038-0_4
Applications of Botulinum Toxin in the Urinary Tract
S. S. Talab (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar